Correlation of clinical data and polymorphism for αィイD21aィエD2-adrenoceptor subtypes gene in Japanese patients with benign prostatic hypertrophy

日本良性前列腺肥大患者临床资料与αD21aD2肾上腺素受体亚型基因多态性的相关性

• 批准号: 09671608
• 负责人: MORIYAMA Nobuo
• 金额: $ 2.3万
• 依托单位: The UNIVERSITY OF TOKYO
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09671608/
• 关键词: Human prostate; Benign prostatic hypertrophy; αィイD21ィエD2-adrenegic receptor; α_1アドレナリン受容体; 多形性

One of αィイD21aィエD2-adrenoceptor subtypes ,αィイD21aィエD2-adrenoceptor is implicated in the pathophysiology of benign prostatic hypertrophy (BPH). We examined polymorphism of the human ala-AR gene (Arg492 to Cys) in 222 BPH patients. There was no significant association of αィイD21aィエD2-adrenoceptor polymorphism with clinical (onset and degree of symptoms, size of BPH and response to αィイD21aィエD2-adrenoceptor blocker) and laboratory data (cholesterol and other lipid data, prostatic specific antigen, testosterone level) of the patient with BPH ; however, the allele frequency in Japan was markedly different from US populations. The results did support the idea that BPH is associated with alterations in αィイD21aィエD2-adrenoceptor gene.

α β D21 α D21 α D2肾上腺素受体是一种肾上腺素受体亚型，与良性前列腺肥大（BPH）的病理生理有关。我们检测了222例BPH患者的ala-AR基因多态性（Arg 492至Cys）。BPH患者的临床（症状的发作和程度、BPH的大小和对α-HAD 21 α-HAD 2-肾上腺素受体阻滞剂的反应）和实验室数据（胆固醇和其他脂质数据、前列腺特异性抗原、睾酮水平）与α-HAD 21 α-HAD 2-肾上腺素受体多态性无显著相关性;然而，日本人群的等位基因频率与美国人群有显著差异。结果支持BPH与α-肾上腺素D21 α-肾上腺素D2受体基因改变有关的观点。

项目成果

Moriyama,N.,et al.: "Semiquantitative evaluation of α_<1a>-adrenoceptor subtype mRNA in human hypertrophied and non-hypertrophied prostates:regional comparison"LIFE SCIENCES. 64. 201-210 (1998)

Moriyama，N.等人：“人肥大和非肥大前列腺中α_1a-肾上腺素受体亚型mRNA的半定量评估：区域比较”LIFE SCIENCES 64. 201-210(1998)。

Taniguchi,N., Ukai,Y., Kimura,K., Tanaka,T., Yano,J., Moriyama,N., et al.: "Identification of α_1-adrenoceptor subtypes in the human prostatic urethra." Naunyn Schmiedeberg's Arch.Pharmacol.355. 412-416 (1997)

Taniguchi, N.、Ukai, Y.、Kimura, K.、Tanaka, T.、Yano, J.、Moriyama, N. 等人：“人类前列腺尿道中 α_1-肾上腺素受体亚型的鉴定”。 Arch.Pharmacol.355。412-416 (1997)

Moriyama,N., et al.: "Immunohistochemical expression of glucose transporter 1 in human penile proliferative lesions." Histochemical J.29. 273-278 (1997)

Moriyama,N. 等人：“人类阴茎增殖性病变中葡萄糖转运蛋白 1 的免疫组织化学表达。”

Homma,Y., Akaza,H., Okada,K., Yokoyama,M., Moriyama,N., et al.: "Preoperative endocrine therapy for clinical stage A2,B,and C prostate cancer : An interim report on short-term effect." Int.J.Urol.4. 144-151 (1997)

Homma,Y.、Akaza,H.、Okada,K.、Yokoyama,M.、Moriyama,N. 等人：“临床 A2、B 和 C 期前列腺癌的术前内分泌治疗：关于短期的中期报告

Moriyama,N., et al.: "KMD-3213,a novel α_<1a>-adrenoceptor antagonist,potently inhibits the functional α_1-adrenoceptor in human prostate." Eur.J.Pharmacol.331. 39-42 (1997)

Moriyama，N.等人：“KMD-3213，一种新型α_1a-肾上腺素受体拮抗剂，有效抑制人前列腺中的功能性α_1-肾上腺素受体。”Eur.J.Pharmacol.331(1997)。